
Charting a Conditional Approval Pathway for Rare Disease Drugs - A Top Priority for a Revamped FDA?
On April 18, U.S. Food and Drug Administration (FDA) Commissioner Marty Makary announced plans to roll-out a new approval pathway for rare disease drugs. Commissioner Makary’s comments build on sentiments expressed across both the patient community and …